DBV Technologies presents VITESSE subgroup data at EAACI 2026
DBV Technologies has presented new subgroup data from its Phase 3 VITESSE study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Istanbul, showing that its VIASKIN Peanut Patch maintained statistically significant efficacy in peanut-allergic children aged four to seven years who also carry common atopic co-morbidities — including asthma, additional food allergies and atopic dermatitis.
The results extend findings from the headline VITESSE readout, which showed a 46.6% response rate for the patch versus 14.9% for placebo at 12 months across the full 654-participant study population. In the co-morbidity subgroups presented at EAACI, response rates followed a similar pattern: 48.3% versus 19.6% in children with asthma (risk difference: 28.8, 95% CI: 15.79–41.76); 46.8% versus 13.6% in those with concomitant food allergies (risk difference: 33.2, 95% CI: 23.50–42.83); and 47.2% versus 13.2% in children with atopic dermatitis (risk difference: 34.0, 95% CI: 25.09–42.94), all at p<0.0001. The co-morbidity burden in the trial was notable: 61.8% of participants had atopic dermatitis and 56.6% had additional food allergies, indicating the study population was broadly reflective of real-world paediatric allergy clinics.
THRIVE study adds infant population
Alongside the VITESSE analysis, DBV previewed the design of its recently initiated Phase 2 THRIVE study, which will enrol approximately 250 infants aged six to twelve months with physician-confirmed peanut allergy. THRIVE is an open-label, single-arm study that will assess whether three years of treatment with the VIASKIN Peanut Patch can enable participants to achieve ad-lib consumption of peanuts. DBV's hypothesis is that the elevated immune responsiveness observed in younger children could support more durable immunomodulation. Professor Kirsten Perrett of the Murdoch Children's Research Institute in Australia, who serves as global co-primary investigator, presented the design on 14 June.
Chief medical officer Pharis Mohideen said the company was "very pleased to see that treatment with the VIASKIN Peanut Patch demonstrated statistically significant efficacy across all allergic comorbidities," and described THRIVE as an opportunity to explore whether earlier intervention may produce higher, sustained immune tolerance.
Market and regulatory context
The peanut allergy immunotherapy market has grown considerably since the FDA's 2020 approval of Palforzia (peanut allergen powder, oral immunotherapy) for children aged four and older. The epicutaneous route taken by VIASKIN offers a mechanistically distinct approach — delivering microgram-level allergen through intact skin rather than by ingestion — which DBV argues may improve tolerability, particularly in young patients with multiple atopic conditions.
DBV is also running separate VIASKIN studies in toddlers aged one to three years, giving the company a tiered paediatric programme that would, if all studies succeed, cover peanut-allergic patients from infancy through early childhood. Regulatory submissions have not yet been filed and the VIASKIN Peanut Patch is not authorised for sale in any market. The subgroup data presented at EAACI are not a new top-line readout but rather a deeper cut of the already-announced VITESSE dataset; investors and regulators will be watching for the company's submission timeline as the next material milestone. The dual listing on Euronext Paris and Nasdaq means both European and US investors will be monitoring any regulatory engagement announcements closely.